Kimia Farma Tbk PT
IDX:KAEF
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
560
1 670
|
| Price Target |
|
We'll email you a reminder when the closing price reaches IDR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Kimia Farma Tbk PT
Kimia Farma Tbk PT
Note Receivable
Kimia Farma Tbk PT
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kimia Farma Tbk PT
IDX:KAEF
|
Note Receivable
Rp3B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
8%
|
|
|
T
|
Tempo Scan Pacific Tbk PT
IDX:TSPC
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kalbe Farma Tbk PT
IDX:KLBF
|
Note Receivable
Rp133.2B
|
CAGR 3-Years
62%
|
CAGR 5-Years
37%
|
CAGR 10-Years
26%
|
|
|
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
|
Note Receivable
Rp9.7B
|
CAGR 3-Years
15%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Soho Global Health Tbk PT
IDX:SOHO
|
Note Receivable
Rp755m
|
CAGR 3-Years
-83%
|
CAGR 5-Years
-61%
|
CAGR 10-Years
N/A
|
|
|
Pyridam Farma Tbk PT
IDX:PYFA
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Kimia Farma Tbk PT
Glance View
PT Kimia Farma Tbk engages in the production and distribution of healthcare products. The company is headquartered in Jakarta, Dki Jakarta and currently employs 11,668 full-time employees. The company went IPO on 2001-07-04. The firm produces medical devices and chemical materials. The firm is also involved in producing vegetable oil, iodine, and salts. Its products include Glucokaf, Diazink, Oracef, Kifarox, Magacid Suspension, Magaside Chewable Tablets, Nitrocafe Retarded, Nitrocafe Retard Forte, Trinolon, Raistine, VAGIZOL, Neviral, Hiviral Tablet, Duviral, Codipront Cum Expectorant, RETHAPHYL SR, and SUPRAFLU. Its generic products include PETHIDIN Hcl, PARACETAMOL, Diclofenac Sodium, MEPHANAMIC ACID, ANTALGIN, ANTASIDE DOEN, PYRANTEL, ALBENDAZOLE, METRONIDAZOLE TABLET, NEO BLOOD ADDING TABLET, FERROUS SULOATE SYRUP, DIMENHYDRINATE, ACYCLOVIR, AMBROXOL HCL, CHLOROQUINE, CHLORPROMAZINE HCL, CODEIN, CLOPIDOGREL, ERGOTAMINE COFFEE, METHYLERGOMETRINE TABLET SALUTE, MELOXICAM, and Pherphenazine.
See Also
What is Kimia Farma Tbk PT's Note Receivable?
Note Receivable
3B
IDR
Based on the financial report for Sep 30, 2024, Kimia Farma Tbk PT's Note Receivable amounts to 3B IDR.
What is Kimia Farma Tbk PT's Note Receivable growth rate?
Note Receivable CAGR 10Y
8%
Over the last year, the Note Receivable growth was -22%. The average annual Note Receivable growth rates for Kimia Farma Tbk PT have been -22% over the past three years , -2% over the past five years , and 8% over the past ten years .
You don't have any saved screeners yet
